Every 424B that CDT Equity Inc. (CDT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CDT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDT filings page.
CDT Equity Inc. is supplementing its resale prospectus for 673,023 shares of common stock offered by selling stockholders. CDT is not selling securities and will receive no proceeds from their resales; selling stockholders may sell any, all or none.
On October 6, 2026, CDT issued a senior secured convertible note with $6,750,000 original principal; it provides for $5,000,000 of funding in two tranches. CDT received $3,000,000 in the first tranche against $4,050,000 of principal before fees; net proceeds were $2,869,850. A further $2,000,000 for the remaining $2,700,000 principal is conditional, including on resale-registration effectiveness and stockholder approval. Repayment is in 24 weekly installments of $168,750 starting October 14, 2026; the note matures March 24, 2027.
The note converts at the greater of 70% of the lowest closing price during the preceding 20 consecutive trading days or a $0.18354 floor, subject to resets; a 4.99% ownership cap may be raised to 9.99% or 19.99% by written notice. The lender received warrants for 225,000 shares at an exercise price of $0.9177 per share. Eighty percent of net proceeds from ATM sales on or after October 6, 2026, must go first to this note.
CDT Equity Inc. is registering 673,023 shares of common stock for resale by selling stockholders. CDT is not selling securities in this offering and will receive no proceeds from their sales; holders may sell any, all or none of the shares. The registered pool includes 485,244 shares issued to Sarborg Limited shareholders, 26,000 shares issued to Sarborg, 140,925 shares issuable to J.J. Astor & Co. under convertible notes, and up to 14,630 shares issuable under warrants. Selling stockholders may sell in public or private transactions at prevailing market prices, prices related to prevailing market prices, or privately negotiated prices.
A 1-for-25 reverse stock split became effective on September 28, 2026, at 5:00 p.m. Eastern Time, combining every 25 issued or outstanding common shares into one. No fractional shares were issued, and holders otherwise entitled to fractions received cash in lieu. CDT said the split was intended to ensure continued compliance with Nasdaq’s bid-price rule. The split left par value unchanged at $0.0001 per share. CDT said outstanding shares would be reduced to approximately 1,124,515 after the split, with proportional adjustments to shares issuable under equity awards, convertible securities and warrants, related exercise prices, and equity-plan reserves.
CDT Equity Inc. (CDT) is registering 16,825,644 shares of common stock for resale by existing selling stockholders, including warrant shares, conversion shares from prior notes, consulting share issuances, and shares issued in the Sarborg Limited transactions; CDT is not selling any securities here and will not receive proceeds from these resales.
The company previously effected a 1-for-10 reverse stock split of its common stock effective July 17, 2026, and all share and price data in the registration are split-adjusted. Separately, CDT entered into a new senior secured convertible promissory note with J.J. Astor & Co. for $2,126,250 principal (funding $1,575,000, net $1,501,850), maturing March 1, 2027 and payable in 24 weekly installments of $88,593.75, together with related warrants for 3,468,500 shares at $0.25 per share.
The note is secured by a first-priority lien on company and subsidiary collateral and is convertible, subject to ownership caps and stockholder approval under Nasdaq rules, at a price equal to the greater of 70% of the lowest 20-day VWAP or a $0.05 floor price, with the floor subject to semi-annual reset based on trading prices. Most net proceeds from CDT’s at-the-market program and other equity financings are required to be applied in a waterfall to repay this and related Astor notes before other uses, and both the note and warrant include anti-dilution and reset mechanics, as well as 4.99%–9.99% beneficial ownership limitations.
CDT Equity Inc. (CDT) is registering up to 16,825,644 shares of common stock for resale by existing security holders, including shares issued or issuable under convertible notes, warrants, consulting arrangements, and equity paid in connection with Sarborg Limited transactions. The company is not selling shares itself and will receive no proceeds from these resales.
The prospectus reflects a 1‑for‑10 reverse stock split effective July 17, 2026 and shows 19,268,220 shares outstanding as of the prospectus date, with a last reported Nasdaq Capital Market price of $0.19 on September 17, 2026. CDT highlights heavy reliance on two lead clinical assets (AZD1656 and AZD5904), ongoing net losses, a going‑concern warning, and material weaknesses in internal control, and discloses highly dilutive financing structures including senior secured convertible notes with variable conversion pricing and large warrant and pre‑funded warrant issuances.
CDT Equity Inc. registers 5,348,058 shares of Common Stock for resale by selling stockholders. The registration covers 925,925 shares issuable under an amended equity line of credit with Ascent Partners Fund LLC and 4,422,133 shares issued in connection with the Sarborg Limited purchase transaction. The Company states it will not receive any proceeds from sales by the selling stockholders and the shares may be sold from time to time at market, negotiated or private prices. The prospectus notes a 1-for-25 reverse stock split effective March 26, 2026 and references an ELOC capacity of $25.0 million.
CDT amends its prospectus supplement to increase the amount of common stock that may be sold under its Sales Agreement with A.G.P./Alliance Global Partners to $76,077,218 as of April 2, 2026. This Amendment upgrades the previously stated offering capacity of $3,556,586 to the larger aggregate amount because the company’s public float exceeded $75.0 million as of March 24, 2026, allowing use of General Instruction I.B.1 of Form S-3. The prospectus notes the company is an emerging growth company and a smaller reporting company, and discloses a last reported sale price of $5.10 per share on April 1, 2026.
CDT Equity Inc. is registering 22,846,452 shares of common stock for resale by existing holders. The shares relate to stock issued for consulting services, an equity line of credit with Ascent Partners Fund, and a sale-and-purchase agreement with Corvus Capital that includes pre-funded warrants.
This is a resale registration, so CDT will not receive proceeds from investors’ purchases under this prospectus. However, a separate equity line allows CDT, at its option, to sell up to $25 million of stock to Ascent over up to 36 months, subject to price and ownership limits.
Corvus, an entity controlled by CDT’s CEO, received CDT shares and 3,685,815 pre-funded warrants as $7,000,000 consideration for acquiring subsidiary CPL and its related litigation exposure. CDT highlights substantial funding needs, an accumulated deficit of $47.0 million as of September 30, 2025, a quarterly net loss of $7.1 million, potential Nasdaq listing risk, and the chance that these resales and any future issuances may significantly dilute existing stockholders and pressure the share price.